Nova Patents
NO2007013I2

Ctl4a receptor, fusion proteins containing it and uses thereof

Abstract

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

160 members in 21 offices

This recordMember, by publication datePriority claim11 more offices are in the list below

Priority claims6

Priority claims
DocumentOfficeKindDate
72361791United States of AmericaA
72361791United States of AmericaA
9205202United States of AmericaW
9205202United States of AmericaW
US19910723617–––
WO1992US05202–––

Members160

Family members, oldest first
DocumentOfficeKind
IE922111A1IrelandA1
CA2110518A1CanadaA1
CA2580812A1CanadaA1
WO9300431A1World Intellectual Property Organization (WIPO)A1
IL102294D0IsraelD0
AU2240092AAustraliaA
MX9203605AMexicoA
FI935795AFinlandA
NO934801D0NorwayD0
ZA924782BSouth AfricaB
NO940228D0NorwayD0
NO20020491LNorwayL
NO934801LNorwayL
IL108374D0IsraelD0
KR940701445ARepublic of KoreaA
PT100637APortugalA
EP0606217A1European Patent Office (EPO)A1
CA2113744A1CanadaA1
FI940270AFinlandA
NO940228LNorwayL
AU5390194AAustraliaA
CA2114353A1CanadaA1
EP0610046A2European Patent Office (EPO)A2
EP0613944A2European Patent Office (EPO)A2
JPH06508989AJapanA
JPH06319548AJapanA
JPH0769914AJapanA
NO951436D0NorwayD0
US5434131AUnited States of AmericaA
IL113343D0IsraelD0
AU661854B2AustraliaB2
CA2146895A1CanadaA1
FI951801AFinlandA
NO951436LNorwayL
AU1645895AAustraliaA
EP0682039A1European Patent Office (EPO)A1
JPH0847391AJapanA
NZ243286ANew ZealandA
NZ264712ANew ZealandA
EP0610046A3European Patent Office (EPO)A3
NO963018D0NorwayD0
IL118890D0IsraelD0
CA2181394A1CanadaA1
NO963018LNorwayL
AU6059096AAustraliaA
EP0757099A2European Patent Office (EPO)A2
EP0613944A3European Patent Office (EPO)A3
US5637481AUnited States of AmericaA
MX9602879AMexicoA
JPH09202800AJapanA
AU682325B2AustraliaB2
US5770197AUnited States of AmericaA
US5773253AUnited States of AmericaA
EP0606217B1European Patent Office (EPO)B1
AT170562TAustriaT
ATE170562T1AustriaT1
AU696664B2AustraliaB2
DE69226871D1GermanyD1
DK0606217T3DenmarkT3
US5844095AUnited States of AmericaA
US5851795AUnited States of AmericaA
ES2123001T3SpainT3
AU701310B2AustraliaB2
US5885579AUnited States of AmericaA
US5885796AUnited States of AmericaA
DE69226871T2GermanyT2
EP0757099A3European Patent Office (EPO)A3
PT100637BPortugalB
US5968510AUnited States of AmericaA
US5977318AUnited States of AmericaA
KR100238712B1Republic of KoreaB1
IL108374AIsraelA
US6090914AUnited States of AmericaA
US6132992AUnited States of AmericaA
JP2002003399AJapanA
JP2002017349AJapanA
NO20020491D0NorwayD0
US2002012989A1United States of AmericaA1
IE20010097A1IrelandA1
NO312465B1NorwayB1
US6482919B2United States of AmericaB2
FI20022285AFinlandA
JP2003012546AJapanA
JP2003096097AJapanA
JP2003174872AJapanA
US6623940B1United States of AmericaB1
FI112082BFinlandB
US2003219876A1United States of AmericaA1
NO316223B1NorwayB1
IL159364D0IsraelD0
EP0757099B1European Patent Office (EPO)B1
AT268818TAustriaT
ATE268818T1AustriaT1
DE69632667D1GermanyD1
JP2004248677AJapanA
IL102294AIsraelA
FI20041632AFinlandA
NO317836B1NorwayB1
ES2223061T3SpainT3
FI115057BFinlandB
Showing 100 of 160